Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 55Neoplasm Metastasis 7Triple Negative Breast Neoplasms 6Ovarian Neoplasms 6Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Advanced Breast Cancer 4Prostatic Neoplasms 3Endometrial Neoplasms 3Carcinoma, Ovarian Epithelial 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Hereditary Sensory and Autonomic Neuropathies 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Solid Tumor 1Solid Malignancies 1Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1Pancreatic Neoplasms 1Neoplasms by Site 1Mesothelioma, Malignant 1Mesothelioma 1Lung Neoplasms 1Liposarcoma 1Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1

Interventions

Nivolumab 8Paclitaxel 6Sirolimus 5Bevacizumab 5temsirolimus 4Pemetrexed 4Ipilimumab 4Docetaxel 4Carboplatin 4ARRY-334543 4Gemcitabine 3Erlotinib Hydrochloride 3olaparib 2linrodostat 2apatinib 2anlotinib 2abemaciclib 2Vorinostat 2Sunitinib 2Magnetic Resonance Spectroscopy 2Irinotecan 2Everolimus 2Doxorubicin 2Dasatinib 2Chlorogenic Acid 2Cetuximab 26-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2vorolanib 1vistusertib 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Cancer × Fulvestrant × Clear all
NCT01394016 2024-09-19

A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
225 enrolled 31 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡